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SUMMARY (250 words) 
Background  
Severe and severe/complicated Clostridium difficile infection (CDI) can result in ICU admission, 
sepsis, toxic megacolon, and death.  In this setting, colectomy is the standard of care but it is 
associated with a 50% mortality.  
 
Aim 
 Evaluate safety and efficacy of a sequential FMT and antibiotic protocol in severe and 
severe/complicated CDI patients who are at high risk for colectomy. 
 
Methods 
All patients with severe and severe/complicated CDI refractory to oral vancomycin ± rectal 
vancomycin and intravenous metronidazole therapy were offered FMT.  Treatment consisted of 
sequential FMTs via colonoscopy with the need for repeat FMT and continued vancomycin 
guided by clinical response and pseudomembranes at colonoscopy.  
 
Results 
A total of 29 patients underwent FMT between July 2013 and August 2014. The overall 
treatment response of endoscopic sequential FMT was 93% (27/29), with 100% (10/10) for 
severe CDI and 89% (17/19) for severe/complicated CDI.  A single FMT was performed in 62%, 
two FMTs were performed in 31%, and three FMTs in 7% of patients. The use of non-CDI 
antibiotics predicted repeat FMT (Odds ratio=17.5).  The 30-day all-cause mortality after FMT 
was 7%, and the cumulative 3-month survival was 76%.  Of the two patients who died within 30 
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days, one underwent colectomy and succumbed to sepsis; the other died from septic shock 
related to CDI. 
 
Conclusions 
We describe the largest reported series of FMT for severe and severe/complicated CDI.  The 
success of a treatment protocol involving FMT and continued vancomycin in selected patients 
was high and warrants further evaluation. 
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INTRODUCTION 
 Two randomized controlled trials and numerous case series support the efficacy of fecal 
microbiota transplantation (FMT) in patients with recurrent Clostridium difficile infection 
(CDI).1,2  Many patients in studies of recurrent disease were relatively healthy outpatients.  
However, 3-10% of patients with CDI progress to a severe life-threatening illness that requires 
colectomy in up to 30% of patients.3  Few studies describe the efficacy of FMT in patients with 
severe or fulminant CDI.4-9  
 In our early clinical experience, we encountered several patients with severe CDI who 
died despite FMT.  In particular, we noted that patients with severe or fulminant CDI and 
extensive pseudomembranes at endoscopy tended to respond poorly to single FMTs. Khoruts et 
al. described a dramatic, but unsustained, improvement in CDI after a single FMT in a patient 
with fulminant CDI and suggested that reinitiation of antibiotics against CDI and repeat FMT 
might be needed for cure in some cases of severe FMT.7  Based on this suggestion and our 
anecdotal experience, we developed a protocol for treatment of severe CDI based on FMT, 
continued vancomycin therapy in patients with extensive pseudomembranes at the time of FMT, 
and repeat FMT for patients without clinical response.  In this report, we describe a 
retrospectively evaluated cohort of 29 consecutive patients treated with this protocol.         
 
PATIENTS AND METHODS 
Definitions 
Severe and severe/complicated CDI were defined as per the 2013 American College of 
Gastroenterology guidelines.10 Diagnosis of CDI was made based upon the presence of diarrhea 
(≥ 3 loose stools/day) and positive stool C. difficile toxin. Severe CDI was defined as a serum 
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albumin < 3g/dl plus either white blood count (WBC) ≥15,000 cells/mm3 or abdominal 
tenderness.  Severe/complicated CDI was defined as any of the following attributable to CDI: 
admission to ICU for CDI, hypotension with or without required use of vasopressors, fever ≥ 
38.5°C, ileus, significant abdominal distention, mental status changes, WBC ≥35,000 cells/mm3 
or <2,000 cells/mm3, serum lactate levels >2.2mmol/l, and end organ failure (e.g. mechanical 
ventilation, renal failure). 10  The Charlson co-morbidity index (age adjusted) was calculated to 
assess disease burden from co-morbid conditions and the likelihood of dying within 1 year 
(http://farmacologiaclinica.info/scales/Charlson_Comorbidity/calc/). 11  Treatment success was 
defined as complete resolution of diarrhea, no further need of anti-CDI therapy, avoidance of 
colectomy, and discharge from the hospital.   
 
Patients 
Consecutive patients admitted to Indiana University Hospital between July 2013 and 
August 2014 with severe and severe/complicated CDI unresponsive to antimicrobial CDI therapy 
(oral vancomycin 500-2000 mg/day or fidaxomicin 400 mg/day and rectal vancomycin 2000 
mg/day in patients with ileus, in combination with or without intravenous metronidazole 1500 
mg/day administered for at least for 5 days).  All patients were being evaluated for colectomy, 
were under evaluation of a multidisciplinary team consisting of a gastroenterologist, internist, 
infectious disease specialist and a surgeon, and were offered the opportunity to receive FMT.  
Patients with precipitous clinical deterioration, who were considered for colectomy before the 5-
day minimum of CDI antimicrobial therapy, were also offered FMT.  
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Treatment protocol  
In the protocol, the following steps were performed: 1) Antibiotics were discontinued 12  
to 24 hours before FMT,  2) Colonic bowel prep (split dose 4 L Golytely) was administered if no 
ileus or obstruction was present,  3) Fresh stool was obtained from either a screened patient-
selected donor or universal donor within 6 hours of the procedure (donor selection, screening for 
relevant communicable diseases, and stool processing were performed as outlined by the Fecal 
Microbiota Transplantation Working Group).12  4) Fifty to 200 grams of stool homogenized in 
300 ml of non-bacteriostatic saline was administered carefully via flexible sigmoidoscopy or 
colonoscopy with assessment for pseudomembranes and injection of FMT either proximal or 
distal to the splenic flexure at the discretion of the endoscopist.  5) Oral vancomycin (125 mg 
every 6 hours) was resumed 24 to 48 hours after FMT for a minimum of 5 days if there were 
pseudomembranes present at colonoscopy.   6) For patients who did not improve by days 6-7, the 
vancomycin was stopped, and bowel prep was administered if no ileus was present.  7) The next 
day (day 7-8), a repeat FMT, from the same donor as the first FMT if patient directed, was 
performed by sigmoidoscopy or colonoscopy.  If pseudomembranes were present, oral 
vancomycin was resumed for an additional 5 days.  If no pseudomembranes were detected, 
antibiotics were not resumed following the repeat FMT.  
Patients with clinical improvement were assessed daily for possible discharge.  If a 
patient could not be discharged due to ongoing CDI-related symptoms, vancomycin was stopped 
on day 12-13 and a 3rd FMT was performed on day 13-14.  Cessation of FMT was based on 
resolution of symptoms. Vancomycin was stopped when patients were improved or when 
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pseudomembranes were no longer present. Patients were prospectively followed after treatment 
completion for evidence of recurrence and adverse events.   
The FMT procedure protocol was approved by Indiana University Health.  Baseline data 
and outcomes were prospectively captured using a research database that had been approved by 
the Institutional Review Board at Indiana University - Purdue University.  
Statistical analysis 
Baseline patient characteristics were analyzed using descriptive statistical methods.  
Continuous variables were summarized using mean ± standard deviation and range values and 
categorical variables were summarized using proportions.  Difference in length of hospital stay 
for patients with severe and severe/complicated CDI was summarized using median and 
interquartile range (IQR) due to the skewness of the data and evaluated using the Wilcoxon rank 
sum test.  A logistic regression model was used to examine the potential risk factors for repeat 
FMT. The evaluated risk factors included patients’ demographic, clinical, and laboratory 
variables such as age, sex, severity of CDI, number of CDI episodes, use of non-CDI antibiotic 
during the same hospitalization, WBC, serum albumin concentration, presence of abdominal 
pain, admission to ICU, presence of toxic megacolon, acute renal failure, immunosuppression, 
Charlson comorbidity index, and source of stool. Due to the large number of potential risk 
factors relative to the sample size, we used a forward stepwise procedure to select important risk 
factors. The effect of the selected risk factors on repeat FMT were obtained using the Firth 
logistic regression model with a penalized likelihood approach due to the small sample size.  
Time to death was analyzed using the Kaplan-Meier approach.  All statistical analysis was 
performed using SPSS software (version 22.0; IBM Corp, Armonk, NU, USA).   
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RESULTS 
Twenty-nine patients were admitted with severe and severe/complicated CDI refractory 
to maximum medical therapy and were considered for colectomy.  All 29 patients opted to 
undergo FMT rather than continued antibiotics or colectomy.  Mean age was 65.2 years ± 17.9 
(range, 25-92); 59% were women and 100% were Caucasian.  Mean white blood cell count ± SD 
(range) was 21 k/mm3 ± 11.2 (5.5-56) and albumin 2.3 g/dL ± 0.36 (1.5-2.9).   A history of 
recurrent CDI was present in 69% (20/29) with an average number of prior CDI episodes of 3 ± 
2.4 (1-12).   Ten (34%) patients had severe CDI and 19 (66%) had severe/complicated CDI.  A 
summary of demographics, baseline clinical, and laboratory data of these two groups is shown in 
Table 1.   
Detailed individual patient’s characteristics including demographic, clinical, laboratory 
data, number of previous CDI episodes, ICU stay, concomitant non-CDI antibiotic use, comorbid 
conditions, and immunosuppression, source and type of stool, number of FMTs received and 
outcomes are described in Table S1 (Online Supporting Material). Twelve of the 19 
severe/complicated patients were in the ICU at the time of FMT and had the following sequelae: 
five patients with toxic megacolon (cecal diameter > 12 cm or rectosigmoid diameter > 6.5 cm); 
seven patients with acute renal failure and hypovolemic/septic shock, four of whom required 
vasopressors, three with mental status changes, and two patients on mechanical ventilation.  Four 
patients were on immunosuppressive medications, and five patients had inflammatory bowel 
disease (three with Crohn’s disease and two with ulcerative colitis).   
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A total of 44 FMTs were administered during the study period.  The source was a patient-
selected donor (n=16) or a universal donor (n=28).  Stool was delivered proximal to the splenic 
flexure in 18 transplants and distal to the splenic flexure in 26 transplants as deemed safe by the 
endoscopist depending on the severity of colitis.  The mean number of FMT administered was 
1.5 (range 1-3).  
The overall success rate at 30 days was 93% (27 of 29).  A summary flowchart of FMT 
results is depicted in Figure1. Outcomes and number of FMTs needed based upon categories of 
severe versus severe/complicated CDI are shown in Table 2.  All ten severe CDI infections had a 
successful outcome, whereas, the severe/complicated patients success rate was 89% (17/19).  
The two treatment failures were: 1) death from sepsis (arterial pH 7.1 at the time of FMT) within 
24 hours of the first FMT, 2) death following colectomy after failing three FMTs in a patient 
who was 6 weeks post-orthotopic liver transplantation.   
Treatment success was achieved with a single FMT in 51% of patients and two FMTs in 38%.  A 
single FMT was sufficient in 7 of 10 (70%) severe CDI cases and 8 of 19 (42%) of 
severe/complicated CDI cases.  Table 2 highlights the results of FMT stratified by CDI severity.  
Pseudomembranes were present in 7 of 10 (70%) of severe and in 14 of 19 (74%) 
severe/complicated cases at the time of initial FMT.  The median length of hospital stay was 10 
days (IQR 6-18 days) for the entire study cohort.  The median length of hospital stay was 9 days 
(IQR 5.2-15.5) in severe CDI patients compared to 11.5 days (IQR 7-23) in severe/complicated 
patients (p-value = 0.16).  Following the first FMT, the median length of hospital stay was 6 
days (IQR 3.25-13) in severe patients and 9 days (IQR 7-23) in severe/complicated patients 
(p=0.26). Median follow-up was 4.5 months (IQR 2.75-8.25).              Evaluation of the risk 
factors for the repeat FMT showed that the use of non-CDI antibiotics during the same 
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hospitalization was significantly associated with repeat FMT.Specifically, 70.6% (12/17) of the 
patients who used non-CDI antibiotics had a repeat FMT while only 8.3% (1/12) of the patients 
without use of non-CDI antibiotics had a repeat FMT. Based on the Firth logistic regression 
model, patients who used non-CDI antibiotics were found to be 17.4 times more likely than those 
who did not use non-CDI antibiotics to have a repeat FMT(Odds ratio=17.5; 95% CI=2.2-135.3; 
p=0.006).   
The overall cumulative survival after FMT was 93% (95% CI: 84%-100%) at 1 month 
and 76% (95% CI: 62%-93%) at 3 months.  A Kaplan-Meier survival curve following the first 
FMT is shown in Figure 2.  Three patients died during the follow-up period due to CDI 
associated causes: the above-mentioned two patients and another patient who responded to the 
initial FMT/vancomycin sequential therapy and was discharged but succumbed to CDI sepsis 
after being treated with antibiotics for a urinary tract infection 92 days following first FMT.  Five 
patients died due to causes unrelated to CDI.  
 
DISCUSSION 
This study is the largest reported experience with FMT for severe and severe/complicated 
CDI in the medical literature.  To our knowledge, the size of this experience exceeds the 
combined size of previous reports.4-9  We combined FMT and selected use of continued 
vancomycin and achieved an overall success rate of 93%.  The size of the trial and the high 
success rate indicate that this protocol deserves additional evaluation for severe and 
severe/complicated CDI.  
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             We found that severely ill patients with CDI were successfully treated in many cases by 
FMT combined with continued vancomycin for patients with pseudomembranes. With the 
application of the current protocol, we achieved a higher success rate in this critically ill 
population than our previous and others’ experience after administration of a single FMT.7,9,13      
One interpretation is that a single FMT in patients with severe and, in particular, in 
severe/complicated CDI with pseudomembranes is insufficient in achieving complete resolution 
of CDI symptoms, but sufficient to decrease the C. difficile burden enabling a response to anti-
CDI therapy.  In the Cammarota trial, where patients with recurrent CDI were randomized to 
FMT versus oral vancomycin, seven had pseudomembranous colitis.13 The first two patients with 
pseudomembranous colitis briefly responded to a single FMT, but ultimately succumbed to CDI-
related death despite delayed reinitiation of vancomycin and/or repeat FMT.  Their findings 
suggest as well that pseudomembranes are indicative of disease severity and a lower likelihood 
of response to a single FMT.  Subsequently, Cammarota and colleagues changed the study 
protocol in which all patients with pseudomembranous colitis were treated with repeat FMTs at 
3-day intervals until the colitis had resolved.  Their short interval between FMT alone achieved a 
high rate of success but it required twice as many FMTs compared to our study with FMT 
alternating with vancomycin (2.8 FMTs vs. 1.5 FMTs).     
In this study, we initially used patient selected donors because it was believed that using a 
house member mitigated the risk of communicable diseases and the donor had a robust 
microbiota protecting them from CDI.14,15  However, recent studies demonstrated that universal 
donors (non-related, volunteers) are just as safe and effective as patient directed donors.16,17  
Over time, we found that using a frozen stool bank greatly simplified the logistics of FMT which 
was key for urgent FMTs for severe and severe/complicated CDI.    
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This study has multiple limitations.  First, as noted above, the importance of the 
individual elements of the protocol and the decision making process is uncertain.  Second, the 
study is observational and not controlled.  However, there is too little information on an optimal 
protocol for patients with severe and severe/complicated disease to currently initiate a controlled 
trial of FMT in this group of patients.  During the study, our goal was to identify a protocol that 
improved the outcome of our seriously ill patients with CDI.  Third, the severity of illness in our 
patients might be different from that in other studies of severe and severe/complicated CDI.  We 
explicitly defined the criteria by which our patients met the definitions of severe and 
severe/complicated CDI (Table S1, Online Supporting Material).  This seems appropriate for all 
investigators developing FMT protocols for this population, as the severity of illness should be 
clearly understood when interpreting the clinical treatment outcomes. Future randomized studies 
might compare these protocols for severe and complicated CDI.  Also, embedding microbiome 
profiling to navigate mechanistic insights, notably the impact of vancomycin on post-FMT 
microbiota, and longer follow-up seem appropriate.   
 In conclusion, given the high colectomy and mortality rates associated with fulminant 
CDI, the success described here indicates that this protocol warrants additional and controlled 
study. 
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